Navigation Links
New Study by BioTrends Highlights Practice Management Shifts Among European Nephrologists

EXTON, Pa., June 5 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the release of TreatmentTrends(TM): European Nephrology Study II. The report is based on the results of an on-line survey completed by 203 clinical nephrologists in the UK, France, Germany, Italy, and Spain. The report focuses on the management of renal anemia, hyperphosphatemia, and secondary hyperparathyroidism.

In the ESA market, Amgen's Aranesp is the market share leader in pre-dialysis and is competing vigorously against Roche's Neorecormon for the top spot in dialysis. An attribute analysis details significant competitive advantages for Aranesp with regard to ease of administration and extended dosing intervals, while performing on par with other ESAs for efficacy, safety, and tolerability. Roche launched Mircera in the EU during the second half of 2007, however, this research suggests that Mircera has not penetrated the ESA market in either the dialysis or pre-dialysis setting. Other newcomer, Shire's Dynepo, also reported stagnant share even though the percent of Nephrologists reporting clinical experience with the product increased over the past six months. Worth noting is the slow uptake of biosimilar ESAs such as Binocrit. While overall share for biosimilars is less than 1% and only German Nephrologists reported use of biosimilars, more than one-third of the respondents expect that the biosimilar agents will be part of their ESA armamentarium in the next six months.

In the phosphate binder market, Shire expanded share of Fosrenol in all five EU markets. 90% of Nephrologists have now tried Fosrenol and use of the product is expected to increase in the next three months, primarily in the dialysis setting. Calcium based binders are still the predominant binders used in pre-dialysis, but with Genzyme's Renagel and Fosrenol taken together, dialysis share for non-calcium agents exceeds 53%. Non-calcium based binders outperform calcium based agents on most product attributes, and among the most important attributes, Renagel holds an advantage over Fosrenol in three out of four. Calcium carbonate, the leading calcium preparation, tends to outperform calcium acetate on most attributes.

With more than one-third of dialysis patients reportedly above the target range for PTH, there is a rather high need for new therapies to treat SHPT. 48% of the Nephrologists surveyed indicated that they have increased their use of Amgen's Mimpara in the past three months. In addition, Mimpara share is projected to increase from 19 % to 22% in the next three months. Abbott's active vitamin D agent, Zemplar, also enjoyed positive gains and 24% of EU Nephrologists agree that Zemplar offers improved morbidity and mortality benefits compared to calcitriol.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. ( provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or visit

All company, brand, or product names contained in this document may be trademarks of their respective holders.

SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. 30, ... BCLI ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd., has been awarded an additional grant of ... the Chief Scientist (OCS). This grant, the second this year, ... activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):